Home
INVESTORS
TraumaPulse Biosystems
Quantifying muscular perfusion to advance safer orthopedic traumatology and beyond. AI-enabled ultrasonic technology transforming trauma diagnostics worldwide.
The Critical Challenge in Trauma Care
Acute Compartment Syndrome (ACS) represents one of orthopedic trauma's most devastating diagnostic challenges. With clinical accuracy plummeting to just 11–15%, missed diagnoses trigger irreversible consequences within a narrow 6-hour window.
The human toll is staggering: over 60% of delayed cases result in amputation, with mortality rates reaching 15%. Current diagnostic methods remain invasive, painful, and provide only fragmented snapshots rather than continuous monitoring.
11%
Diagnostic Accuracy
Current ACS detection methods
6hrs
Critical Window
Before irreversible damage
60%
Amputation Risk
From missed diagnoses
$426K
Average Settlement
Per malpractice case
Quadplex Ultrasound™ Technology
TraumaPulse transforms standard hospital ultrasound systems into sophisticated, continuous perfusion monitoring platforms. Our proprietary Quadplex Ultrasound™ technology synchronizes four diagnostic modes simultaneously, processing over 10,000 signals per second into actionable real-time perfusion maps.
B-Mode Anatomy
Baseline structural visualization for precise anatomical reference and tissue identification
Color Doppler Flow
Dynamic perfusion distribution mapping across compartment tissues
Spectral Doppler
Velocity and pulsatility waveform analysis for detailed hemodynamic assessment
Compliance Sensing
Phase-sensitive micromotion detection measuring tissue stiffness and compartment pressure
Non-invasive. Continuous. Hardware-agnostic. AI-driven. — The future of trauma diagnostics.
Transformative Market Opportunity
Global Hospital Network
170,000+ hospitals worldwide with 12,000+ facilities across North America representing immediate deployment opportunities
Economic Impact
Preventing unnecessary fasciotomies saves $45,000–$80,000 per case in the U.S., with extended stays costing $12,000 daily
Regulatory Pathway
SaMD clearance via FDA 510(k) and CE MDR Rule 11 frameworks accelerates market entry
Adoption Potential
Conservative penetration of just 200 hospitals sustains approximately $1 billion valuation. The global medical device market projects $800B by 2030, with trauma care representing a rapidly expanding segment growing 8% annually.
Platform Expansion Strategy
TraumaPulse Biosystems anchors a comprehensive perfusion diagnostics platform with expansive clinical applications. Our technology evolution follows a strategic two-pronged approach: TraumaPulse leading orthopedic traumatology innovation, complemented by CerebroPulse advancing neurological monitoring and pharmaceutical safety.
01
TraumaPulse Core
ACS detection and orthopedic trauma monitoring establishing clinical validation and market presence
02
CerebroPulse Extension
ARIA drug safety monitoring and intracranial pressure assessment for neurology applications
03
Broader Clinical Applications
Burn perfusion assessment, organ congestion monitoring, transplant viability evaluation
04
Emergency Medicine
Sepsis perfusion tracking, neuromuscular triage, and obstetric monitoring solutions

Research Use Only (RUO) Foundation: TraumaPulse provides AI-ultrasonic muscular perfusion data for orthopedic traumatology trials, healthcare research, and medical screening purposes under current regulatory framework.
World-Class Leadership Team
Our exceptional team combines clinical frontline experience, regulatory mastery, and groundbreaking scientific innovation. This unique convergence of expertise positions TraumaPulse to revolutionize trauma diagnostics globally.
John Nguyen, CEO
Visionary strategist and architect of Quadplex Ultrasound™ technology. Proven medtech founder with successful exits and deep commercialization expertise in healthcare innovation.
Chief Medical Officer
Board-certified trauma and orthopedic surgeon with extensive frontline ACS experience. Translates clinical insights into product requirements and validation protocols.
Chief Technology Officer
Biophysics specialist and IP architect behind compliance sensing innovation. Holds multiple patents in ultrasonic signal processing and AI-driven diagnostics.
Chief Regulatory Officer
Seasoned regulatory veteran with proven FDA 510(k) and CE MDR clearance track record. Navigates complex approval pathways with strategic precision.
Distinguished Advisory Board
  • Former NASA scientist with 270+ peer-reviewed publications
  • Ultrasound technology pioneer holding 40+ patents
  • Clinical key opinion leaders in trauma and orthopedics
  • Healthcare economics and reimbursement strategists
"Our team transforms clinical suspicion into diagnostic certainty—blending frontline trauma experience with breakthrough engineering and regulatory excellence."
Scalable Business Model
TraumaPulse leverages a capital-efficient, software-only architecture that scales exponentially without physical manufacturing constraints. Our dual-revenue model combines predictable SaaS subscriptions with strategic OEM partnerships.
This approach eliminates traditional medtech barriers—no probes, no factories, no inventory overhead. Software-as-Medical-Device (SaMD) classification accelerates deployment while maximizing gross margins.
Hospital Subscriptions
$45,000–$250,000 annual licensing per facility based on bed count and utilization volume
OEM Licensing
Strategic partnerships with ultrasound manufacturers featuring upfront payments plus recurring royalties
Global Scaling
Software-only distribution enables rapid international expansion with minimal capital requirements
85%
Gross Margin Potential
Software-driven model with minimal COGS
3x
Revenue Multiple
SaMD companies vs hardware peers
170K
Hospital TAM
Global addressable market
Join the Revolution in Trauma Diagnostics
Saving Limbs. Saving Lives. Scaling Innovation.
TraumaPulse Biosystems stands at the forefront of a diagnostic revolution. Our Quadplex Ultrasound™ technology transforms every compatible ultrasound system into a sophisticated perfusion monitoring platform, bringing precision to one of medicine's most challenging diagnostic scenarios.
We invite forward-thinking investors, hospital systems, and strategic partners to join us in advancing trauma care worldwide. Together, we can eliminate preventable amputations, reduce healthcare costs, and establish new standards of care across orthopedic traumatology and beyond.
Explore Technology
Discover how Quadplex Ultrasound™ revolutionizes perfusion monitoring
See ACS Impact
Understand the clinical and economic imperative
Meet the Team
Connect with our world-class leadership and advisors
Investor Highlights
Review market opportunity and business fundamentals
TraumaPulse Biosystems | Quantifying Muscular Perfusion | AI-Ultrasonic Innovation for Safer Healthcare